Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
Astria Therapeutics, a biopharmaceutical company developing a potential treatment for hereditary angioedema (HAE), announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting on 11 November 2023 at 12:35pm Pacific Standard Time (PST).
Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present additional data from the Phase 1a clinical trial of STAR-0215 in a poster titled, “Support for STAR-0215 Administered Every Three- or Six-Months for Hereditary Angioedema: Phase 1a Results” at 12:35pm PST in the ePoster Section – Exhibit Hall, Monitor 12, presentation number P066.
(Source: Astria)
